本文選題：腫瘤 + 鱗狀細(xì)胞��； 參考：《中國(guó)耳鼻咽喉頭頸外科》2016年04期

【摘要】：目的運(yùn)用miRNA芯片篩選與喉咽鱗狀細(xì)胞癌對(duì)TPF方案誘導(dǎo)化療敏感性相關(guān)的差異miRNAs,生物信息學(xué)分析確定具有診療價(jià)值的目標(biāo)miRNA并進(jìn)行驗(yàn)證。方法利用Affymetrix GeneChipmiRNAArray4.0芯片對(duì)12例TPF方案誘導(dǎo)化療敏感的原發(fā)喉咽鱗狀細(xì)胞癌患者及9例不敏感的患者的腫瘤組織行差異miRNA的篩選。選擇文獻(xiàn)中已經(jīng)報(bào)道的和腫瘤發(fā)生相關(guān)的miRNA作為目標(biāo)miRNA,并采用RT-PCR在24例原發(fā)喉咽鱗癌腫瘤組織(14例敏感,10例不敏感)中驗(yàn)證目標(biāo)miRNA。結(jié)果篩選出24個(gè)miRNA在敏感組與不敏感組間表達(dá)有顯著差異,其中6個(gè)miRNA在對(duì)TPF方案誘導(dǎo)化療敏感組中表達(dá)上調(diào),18個(gè)miRNA表達(dá)下調(diào)。運(yùn)用miRNA靶基因預(yù)測(cè)數(shù)據(jù)庫mirfocus對(duì)篩選出的24個(gè)差異miRNA進(jìn)行分析,確定在敏感組中低表達(dá)的hsa-miR-211-3p、hsa-miR-4253、hsa-miR-4443、hsa-miR-193b-3p作為目標(biāo)miRNA。采用RT-PCR對(duì)目標(biāo)miRNA進(jìn)行驗(yàn)證,hsa-miR-4253、hsamiR-4443、hsa-miR-193b-3p與芯片篩選結(jié)果一致。結(jié)論hsa-miR-4253、hsa-miR-4443、hsa-miR-193b-3p在誘導(dǎo)化療敏感組與不敏感組間有顯著性差異,可作為治療方案的選擇指標(biāo),并為進(jìn)一步研究喉咽鱗狀細(xì)胞癌對(duì)誘導(dǎo)化療敏感性奠定分子生物學(xué)基礎(chǔ)。
[Abstract]:Objective to screen the difference in sensitivity of larynx squamous cell carcinoma (LSCC) to TPF induced chemotherapy by using miRNA microarray, and to identify the target miRNA with diagnostic and therapeutic value by bioinformatics analysis and verify it. Methods Affymetrix GeneChipmiRNAArray4.0 microarray was used to screen the tumor tissues of 12 patients with primary larynx squamous cell carcinoma and 9 insensitive patients with TPF regimen induced chemotherapy-sensitive primary larynx squamous cell carcinoma (LSCC). The miRNA related to tumorigenesis in the literature was selected as the target miRNAs, and RT-PCR was used to validate the target miRNAs in 24 cases of primary larynx squamous cell carcinoma (LSCC) in 14 cases of sensitive tumor tissues and 10 cases of insensitivity). Results the expression of 24 miRNA was significantly different between sensitive group and insensitive group. 6 miRNA were up-regulated and 18 miRNA down-regulated in chemosensitive group induced by TPF regimen. MiRNA target gene prediction database (mirfocus) was used to analyze 24 differentially screened miRNA, and hsa-miR-211-3psa-miR-4253 hsa-miR-4443 hsa-miR-193b-3p was identified as the target of miRNAs. RT-PCR was used to verify the target miRNA. The results of hsa-miR-4253hsamiR-4443hsa-miR-193b-3p were consistent with those of the chip. Conclusion hsa-miR-4253hsa-miR-4443 hsa-miR-193b-3p has a significant difference between chemosensitive and insensitive groups, and can be used as a selective index for the treatment of laryngopharyngeal squamous cell carcinoma. It also provides a molecular biological basis for further study on the sensitivity of larynx squamous cell carcinoma to induced chemotherapy.
【作者單位】： 首都醫(yī)科大學(xué)附屬北京同仁醫(yī)院耳鼻咽喉頭頸外科耳鼻咽喉頭頸科學(xué)教育部重點(diǎn)實(shí)驗(yàn)室(首都醫(yī)科大學(xué));
【基金】：北京市醫(yī)管局揚(yáng)帆計(jì)劃(XMLX201311) 北京市科委重點(diǎn)項(xiàng)目(Z141107002514003)聯(lián)合資助
【分類號(hào)】：R739.6

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王宏亮;喉咽返流治療后癥狀改善先于體征改善[J];國(guó)外醫(yī)學(xué).耳鼻咽喉科學(xué)分冊(cè);2002年05期

2 王進(jìn),王榮光,韓東一,楊偉炎;喉咽反流[J];國(guó)外醫(yī)學(xué).耳鼻咽喉科學(xué)分冊(cè);2005年05期

3 方紅雁;;喉咽反流與質(zhì)子泵抑制劑[J];中國(guó)醫(yī)學(xué)文摘(耳鼻咽喉科學(xué));2010年05期

4 蔡銀君;;中西醫(yī)結(jié)合治療喉咽反流臨床觀察[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2011年02期

5 伍友生;;喉咽寧口服液被批準(zhǔn)上臨床[J];中成藥;1992年02期

6 ;部分喉咽缺損的Ⅰ期修復(fù)[J];國(guó)外醫(yī)學(xué)(耳鼻咽喉科學(xué)分冊(cè));1998年04期

7 宋琦;李曉明;;梨狀窩癌使用殘喉進(jìn)行喉咽重建[J];中國(guó)醫(yī)學(xué)文摘(耳鼻咽喉科學(xué));2008年06期

8 呂正華,欒信庸,潘新良,解光,許風(fēng)雷,劉大昱,雷大鵬;喉咽后壁區(qū)癌手術(shù)治療[J];中國(guó)耳鼻咽喉頭頸外科;2005年04期

9 蘇秀芹;;清喉咽含片成型工藝的研究[J];光明中醫(yī);2012年08期

10 羊美政;楊秀葉;;喉咽及喉功能重建術(shù)后護(hù)理體會(huì)[J];護(hù)士進(jìn)修雜志;1986年03期

相關(guān)會(huì)議論文 前2條

1 嵇慶海;朱永學(xué);李端樹;王弘士;;甲狀腺乳頭狀腺癌侵犯喉咽的外科治療[A];2000全國(guó)腫瘤學(xué)術(shù)大會(huì)論文集[C];2000年

2 徐艷麗;黃沂傳;陳可峰;王濤;李薇;;CK13、FAPa在喉咽鱗癌中的表達(dá)及其與腫瘤的臨床關(guān)系[A];全國(guó)耳鼻咽喉頭頸外科中青年學(xué)術(shù)會(huì)議論文匯編[C];2012年

相關(guān)重要報(bào)紙文章 前1條

1 田玉斌;要把中聲區(qū)作為橋梁和通路來解決[N];音樂周報(bào);2006年

相關(guān)碩士學(xué)位論文 前1條

1 齊智偉;喉咽反流的臨床分析[D];河北醫(yī)科大學(xué);2010年

，

本文編號(hào)：1788343